CD4 and cancer: After oral antibiotic administration, the unique TME of PDAC, characterized by IL-17A CD4 Th17 cells that inhibit the differentiation of anti-cancer IFN-γ CD4 Th1 cells, exhibited a significant reduction in tumor burden and a shift toward immunogenicity, with the shift being particularly evident in the context of adaptive immune responses 248.